Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition

[1]  T. McKinsey,et al.  Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition , 2014, Journal of Translational Medicine.

[2]  M. Humbert,et al.  An Update on Medical Therapy for Pulmonary Arterial Hypertension , 2013, Current Hypertension Reports.

[3]  L. Farkas,et al.  Blocking Macrophage Leukotriene B4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension , 2013, Science Translational Medicine.

[4]  H. Ghofrani,et al.  Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.

[5]  R. Rafikov,et al.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. , 2013, Free radical biology & medicine.

[6]  L. Farkas,et al.  New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis , 2012, Pulmonary circulation.

[7]  M. Humbert,et al.  The study of risk in pulmonary arterial hypertension , 2012, European Respiratory Review.

[8]  W. Seeger,et al.  The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats , 2011, BMC Pharmacology.

[9]  S. Groshong,et al.  Modern age pathology of pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[10]  L. Farkas,et al.  The monocrotaline model of pulmonary hypertension in perspective. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[11]  J. Klinger.  Tadalafil for the treatment of pulmonary arterial hypertension , 2011, Expert review of respiratory medicine.

[12]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[13]  Kurt R Stenmark,et al.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[14]  F. Torres,et al.  Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension , 2009, Expert opinion on pharmacotherapy.

[15]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[16]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[17]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[18]  M. Frid,et al.  Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .

[19]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[20]  E. Olson,et al.  A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  E. Olson,et al.  Independent Signals Control Expression of the Calcineurin Inhibitory Proteins MCIP1 and MCIP2 in Striated Muscles , 2000, Circulation research.